Pharma company Boehringer Ingelheim shifts account from Zenith to OMD

Pharmaceutical company Boehringer Ingelheim has named OMD to manage global media duties for its animal health category. Marketing understands that the assignment covers Asia Pacific, EMEA and the US and will involve cross media, cross channel planning and buying.

The billings are estimated to be from US$90 million to US$100 million and the remit includes tick prevention spray FRONTLINE and beef-flavoured chew NexGuard, Marketing understands.

In a statement to Marketing, Zenith’s spokesperson said: “Boehringer Ingelheim is a global client of Zenith. In Singapore, it hasn’t been an active business.”

Boehringer Ingelheim was established in 1885 and aims to improve the health of humans and animals. It focuses on diseases for which no satisfactory treatment option exists to date, and develops innovative therapies that can extend patients’ lives. Last year, it achieved net sales of about 17.5 billion euros. It also had an R&D expenditure of about 3.2 billion euros.